

SUPPLEMENTARY TABLE S3. IMMUNOLOGICAL AND VIROLOGICAL PARAMETERS EVALUATED IN SIMIAN IMMUNODEFICIENCY VIRUS-INFECTED, COMBINATION ANTIRETROVIRAL THERAPY-TREATED MACAQUES

	<i>Medians with IQR</i>				<i>p^a</i>		
	<i>Baseline^b</i>	<i>Acute infection^c</i>	<i>Post-cART 1</i>	<i>Post-cART 2</i>	<i>Baseline^b vs. acute infection^c</i>	<i>Acute infection^c vs. post-cART 1^d</i>	<i>Post-ART 1^d vs. post-cART 2^e</i>
Plasma							
Viral load (copies/mL)	30 (30–30)	1.34 × 10 ⁶ (3.78 × 10 ⁵ –1.27 × 10 ⁷)	161 (65–2,034)	68 (30–552)	<0.0001	<0.0001	0.0032
sCD14 (ng/mL)	471 (381–616)	660 (533–760)	606 (512–771)	763 (474–905)	0.0039	0.0024	0.0024
Blood							
CD3 ⁺ CD4 ⁺ (cells/μL)	1,102 (975–1,372)	660 (520–901)	1,010 (806–1,135)	958 (754–1,088)	<0.0001	0.0053	0.8901
CD4/CD8 ratio	1.7 (1.3–2.1)	1.0 (0.8–1.4)	1.1 (0.9–1.7)	1.2 (1.0–1.5)	<0.0001	0.0033	0.0024
Colon							
CD4 (%)	52.6 (42.3–61.2)	13.4 (6.8–19.2)	21.9 (16–29.3)	36.3 (21.2–49.0)	<0.0001	<0.0001	0.0003
CD4/CD8 ratio	1.5 (1.1–2.0)	0.2 (0.1–0.3)	0.4 (0.3–0.6)	0.7 (0.5–1.1)	<0.0001	<0.0001	0.002
Th17 (%)	10.3 (7.5–16.1)	4.3 (1.8–10.2)	5.0 (2.6–7.3)	4.6 (2.0–8.1)	0.0361	0.8288	0.5678
Treg (%)	2.3 (1.6–4.5)	12.0 (5.9–17.9)	3.8 (3.4–5.5)	6.6 (4.3–11.5)	<0.0001	0.5949	0.0029
Th17/Treg ratio	2.1 (1.5–3.3)	0.2 (0.1–0.4)	0.4 (0.3–0.5)	0.4 (0.1–0.6)	<0.0001	0.5949	0.6794
Th17 polyfunc. (%) ^f	5.7 (3.6–7.5)	1.2 (0.5–2.8)	1.3 (0.7–2.1)	1.1 (0.6–2.4)	0.0018	0.5949	0.8596
Ki67 ⁺ /CD4 ⁺ (%)	3.9 (3.2–4.9)	11.1 (5.5–20.6)	7.6 (4.6–9.8)	5.0 (4.3–9.5)	0.0005	0.0289	0.8288
Ki67 ⁺ /CD8 ⁺ (%)	5.5 (3.5–6.9)	10.5 (6.0–22.2)	6.0 (2.8–9.2)	4.3 (3.2–7.0)	0.0028	0.0204	0.002
MLN							
CD4 (%)	66.7 (52.7–69.1)	N/A	62.5 (55.9–65.9)	68.7 (65.0–74.1)	0.0013	N/A	<0.0001
CD4/CD8 ratio	2.4 (2.1–2.7)	N/A	2.1 (1.8–2.2)	2.5 (2.0–3.2)	0.0797	N/A	0.1815
Th17 (%)	2.2 (1.8–3.4)	N/A	1.5 (0.8–1.8)	1.7 (0.99–2.9)	0.0129	N/A	0.0139
Treg (%)	2.6 (1.7–3.4)	N/A	2.8 (1.8–4.9)	4.1 (3.2–6.1)	0.3778	N/A	0.0116
Th17/Treg ratio	1.0 (0.8–1.6)	N/A	0.6 (0.4–1.0)	0.4 (0.1–0.8)	0.0005	N/A	0.0483
Ki67 ⁺ /CD4 ⁺ (%)	0.7 (0.6–0.8)	N/A	1.8 (1.3–3.0)	1.7 (1.1–2.3)	<0.0001	N/A	0.6477
Ki67 ⁺ /CD8 ⁺ (%)	1.3 (1.0–1.4)	N/A	3.3 (2.0–3.8)	2.5 (2.3–4.5)	<0.0001	N/A	>0.9999
PBMC							
CM CD4 ⁺	9.9 (6.3–12.8)	6.7 (5.1–8.8)	9.2 (6.2–11.3)	9.4 (8.2–11.7)	0.0230	0.0616	0.0062
TIGIT ⁺ CM CD4 ⁺	4.5 (2.9–4.9)	7.5 (4.1–8.0)	8.3 (6.9–11.7)	8.1 (6.0–9.1)	0.0034	0.1688	0.1336
TIGIT ⁺ CM CD8 ⁺	3.4 (3.1–5.9)	6.4 (4.5–8.2)	6.5 (5.3–8.8)	7.7 (5.3–11.2)	0.0071	0.0602	0.0304

^aUnadjusted paired Wilcoxon tests were used to generate *p*-values; *p* < 0.05 is considered significant.

^bBaseline: 0 wpi (plasma); –4 wpi (blood, PBMC, colon, MLN).

^cAcute infection: 6 wpi (plasma, colon, PBMC); 4 wpi (blood); N/A (MLN).

^d2–4 Weeks post-cART: 2 weeks on cART (blood, PBMC, colon, MLN); 4 weeks on cART (plasma).

^e22–26 Weeks post-cART: 22 weeks on cART [blood (CD4 count), PBMC, colon, MLN]; 26 weeks on cART [blood (CD4/CD8)].

^fTh17 Polyfunc. (%): polyfunctional was defined as the percentage of cells expressing IL-17 and ≥2 additional cytokines (IL-22, IFN γ , TNF α , or IL-2).

cART, combination antiretroviral therapy; CM, central memory; IL; IQR, interquartile range; MLN, mesenteric lymph node; N/A, not available; PBMC, peripheral blood mononuclear cells; polyfunc., polyfunctional; wpi, weeks post infection.